Literature DB >> 11451763

AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association.

J Hirsh, S S Anand, J L Halperin, V Fuster.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11451763     DOI： 10.1161/hq0701.093520

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  6 in total

1.  Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia.

Authors:  Vincent Hayes; Ian Johnston; Gowthami M Arepally; Steven E McKenzie; Douglas B Cines; Lubica Rauova; Mortimer Poncz
Journal:  J Clin Invest       Date:  2017-02-20       Impact factor: 14.808

2.  Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

Authors:  Qing Ma; Mahmut Tobu; Christopher Schultz; Walter Jeske; Debra Hoppensteadt; Jeanine Walenga; Umberto Cornelli; John Lee; Robert Linhardt; Israel Hanin; Jawed Fareed
Journal:  Thromb Res       Date:  2006-07-07       Impact factor: 3.944

3.  Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-dependent pathways.

Authors:  Hui Xie-Zukauskas; Jharna Das; Billie Lou Short; J Silvio Gutkind; Patricio E Ray
Journal:  Vascul Pharmacol       Date:  2012-12-23       Impact factor: 5.773

Review 4.  The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications.

Authors:  Bethanie I Ayerst; Catherine L R Merry; Anthony J Day
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-13

5.  Growth Differentiation Factor 5-Mediated Enhancement of Chondrocyte Phenotype Is Inhibited by Heparin: Implications for the Use of Heparin in the Clinic and in Tissue Engineering Applications.

Authors:  Bethanie I Ayerst; Raymond A A Smith; Victor Nurcombe; Anthony J Day; Catherine L R Merry; Simon M Cool
Journal:  Tissue Eng Part A       Date:  2017-01-06       Impact factor: 3.845

6.  Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.

Authors:  Frans Moll; Iris Baumgartner; Michael Jaff; Chuke Nwachuku; Marco Tangelder; Gary Ansel; George Adams; Thomas Zeller; John Rundback; Michael Grosso; Min Lin; Michele F Mercur; Erich Minar
Journal:  J Endovasc Ther       Date:  2018-04       Impact factor: 3.487
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.